Stock Traders Purchase Large Volume of Edwards Lifesciences Call Options (NYSE:EW)

Edwards Lifesciences Corporation (NYSE:EW) saw unusually large options trading activity on Monday. Traders acquired 2,518 call options on the company. This represents an increase of 93% compared to the average daily volume of 1,303 call options.

Wall Street Analyst Weigh In

Several research firms have commented on EW. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Royal Bank Of Canada lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. UBS Group started coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective for the company. Finally, Wall Street Zen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Saturday. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Price Performance

EW traded up $1.35 during trading on Monday, reaching $85.72. The company’s stock had a trading volume of 714,015 shares, compared to its average volume of 4,583,936. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $89.16 and a two-hundred day simple moving average of $85.81. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $96.29. The company has a market cap of $49.36 billion, a price-to-earnings ratio of 49.25, a PEG ratio of 2.21 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the business earned $0.67 earnings per share. The business’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts anticipate that Edwards Lifesciences will post 3 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,664 shares of company stock valued at $511,918 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently modified their holdings of EW. California State Teachers Retirement System increased its position in Edwards Lifesciences by 9,187.8% during the second quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock worth $7,323,828,000 after purchasing an additional 80,090,362 shares during the last quarter. BlackRock Inc. acquired a new position in Edwards Lifesciences in the 2nd quarter valued at about $5,318,092,000. State Street Corp boosted its holdings in Edwards Lifesciences by 1.5% in the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after purchasing an additional 371,892 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Edwards Lifesciences by 4.8% in the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after purchasing an additional 989,533 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $1,274,082,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.